US2011288156A1PendingUtilityA1

Nucleic Acids, Polypetides, and Methods for Modulating Apoptosis

48
Assignee: TAYLOR CATHERINEPriority: Jul 23, 2001Filed: Jun 27, 2011Published: Nov 24, 2011
Est. expiryJul 23, 2021(expired)· nominal 20-yr term from priority
Inventors:Catherine TaylorTzann-Wei WangLarry PetrovJohn C. CarlsonRichard NarayansinghJohn E. Thompson
A61P 3/10A61P 37/04A61P 37/08A61P 9/00A61P 43/00A61P 9/04A61P 37/06A61P 35/04A61P 37/02A61P 9/10A61P 25/28A61P 31/18A61P 27/02A61P 31/04A61P 31/12A61P 25/14A61P 25/00A61P 35/00A61P 27/06A61P 35/02A61P 29/00A61P 25/16A61P 25/08A61P 19/02C12Q 1/6876A61P 11/06A61P 19/10C12Q 2600/158A61P 17/02A61P 21/04A61P 13/10A61P 13/12C12N 15/1136C12N 9/0004A61P 17/00C07K 14/4747C12N 15/1137C07K 14/47C12N 15/11A61P 1/16A61K 48/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific and DHS useful in such methods.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . A method of modulating apoptosis in a cell comprising administering to the cell an agent that modulates apoptosis-specific eIF-5A function. 
     
     
         14 . The method of  claim 13 , wherein the agent inhibits apoptosis-specific eIF-5A function, thereby inhibiting apoptosis. 
     
     
         15 . The method of  claim 14 , wherein the agent is an antisense oligonucleotide. 
     
     
         16 . The method of  claim 15 , wherein the antisense oligonucleotide comprises a nucleotide sequence encoding a portion of an apoptosis-specific eIF-5A polypeptide. 
     
     
         17 . The method of  claim 16 , wherein the antisense oligonucleotide comprises SEQ ID NO: 19, 20, or 21. 
     
     
         18 . The method of  claim 15 , wherein the antisense oligonucleotide comprises a nucleotide sequence encoding a portion of an apoptosis-specific DHS polypeptide. 
     
     
         19 . The method of  claim 15 , wherein the agent is a chemical or drug that inhibits apoptosis-specific eIF-5A function. 
     
     
         20 . The method of  claim 13 , wherein the agent inhibits apoptosis-specific DHS function, thereby inhibiting apoptosis. 
     
     
         21 . The method of  claim 20 , wherein the agent is an antisense oligonucleotide. 
     
     
         22 . The method of  claim 21 , wherein the antisense oligonucleotide comprises a nucleotide sequence encoding a portion of an apoptosis-specific eIF-5A polypeptide. 
     
     
         23 . The method of  claim 22 , wherein the nucleotide sequence comprising SEQ ID NO: 19, 20, or 21. 
     
     
         24 . The method of  claim 21 , wherein the antisense oligonucleotide comprises a nucleotide sequence encoding a portion of an apoptosis-specific DHS polypeptide. 
     
     
         25 . The method of  claim 20 , wherein the agent is a chemical or drug that inhibits apoptosis-specific DHS function. 
     
     
         26 . The method of  claim 13 , wherein the agent increases apoptosis-specific eIF-5A function, thereby inducing apoptosis in the cell. 
     
     
         27 . The method of  claim 26 , wherein the agent comprises an expression vector. 
     
     
         28 . The method of  claim 27 , wherein the expression vector comprises a promoter sequence operably linked to a nucleotide sequence encoding an apoptosis-specific eIF-5A polypeptide. 
     
     
         29 . The method of  claim 27 , wherein the expression vector comprises a promoter sequence operably linked to a nucleotide sequence encoding an apoptosis-specific DHS polypeptide. 
     
     
         30 . The method of  claim 13 , wherein the agent increases apoptosis-specific DHS function, thereby inducing apoptosis in the cell. 
     
     
         31 . The method of  claim 30 , wherein the agent comprises an expression vector. 
     
     
         32 . The method of  claim 31 , wherein the expression vector comprises a promoter sequence operably linked to a nucleotide sequence encoding an apoptosis-specific eIF-5A polypeptide. 
     
     
         33 . The method of  claim 31 , wherein the expression vector comprises a promoter sequence operably linked to a nucleotide sequence encoding an apoptosis-specific DHS polypeptide. 
     
     
         34 . The method of  claim 13 , wherein the cell is comprised within an animal. 
     
     
         35 . The method of  claim 34 , wherein the agent is administered to the animal. 
     
     
         36 - 63 . (canceled)

Join the waitlist — get patent alerts

Track US2011288156A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.